CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Y-mAbs Therapeutics, Inc. - YMAB CFD

    5.20
    2.56%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Y-mAbs Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 5.07
    Open* 4.99
    1-Year Change* -64.96%
    Day's Range* 4.99 - 5.22
    52 wk Range 2.70-16.92
    Average Volume (10 days) 132.12K
    Average Volume (3 months) 4.61M
    Market Cap 218.54M
    P/E Ratio -100.00K
    Shares Outstanding 43.62M
    Revenue 84.99M
    EPS -0.89
    Dividend (Yield %) N/A
    Beta 0.70
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 5.20 0.22 4.42% 4.98 5.22 4.98
    Sep 21, 2023 5.07 0.14 2.84% 4.93 5.16 4.93
    Sep 20, 2023 5.17 -0.01 -0.19% 5.18 5.34 5.04
    Sep 19, 2023 5.21 0.36 7.42% 4.85 5.35 4.85
    Sep 18, 2023 5.05 0.19 3.91% 4.86 5.08 4.86
    Sep 15, 2023 4.97 0.21 4.41% 4.76 5.05 4.74
    Sep 14, 2023 4.96 0.15 3.12% 4.81 5.04 4.78
    Sep 13, 2023 4.93 0.14 2.92% 4.79 5.14 4.79
    Sep 12, 2023 4.98 -0.08 -1.58% 5.06 5.13 4.88
    Sep 11, 2023 5.14 0.05 0.98% 5.09 5.23 4.92
    Sep 8, 2023 5.05 0.10 2.02% 4.95 5.21 4.80
    Sep 7, 2023 4.97 0.18 3.76% 4.79 5.00 4.71
    Sep 6, 2023 4.83 -0.03 -0.62% 4.86 4.95 4.69
    Sep 5, 2023 4.90 -0.28 -5.41% 5.18 5.28 4.82
    Sep 1, 2023 5.27 0.30 6.04% 4.97 5.31 4.84
    Aug 31, 2023 5.03 -0.24 -4.55% 5.27 5.37 5.03
    Aug 30, 2023 5.37 0.01 0.19% 5.36 5.55 5.32
    Aug 29, 2023 5.50 0.23 4.36% 5.27 5.60 5.27
    Aug 28, 2023 5.43 0.15 2.84% 5.28 5.56 5.28
    Aug 25, 2023 5.54 -0.12 -2.12% 5.66 5.71 5.40

    Y-mAbs Therapeutics, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Y-mAbs Therapeutics Inc Earnings Release
    Q3 2023 Y-mAbs Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 65.267 34.897 20.75 0 0
    Total Operating Expense 160.078 150.33 140.685 83.004 43.23
    Selling/General/Admin. Expenses, Total 60.939 54.571 44.785 19.512 8.961
    Research & Development 91.572 93.245 93.697 63.492 34.269
    Operating Income -94.811 -115.433 -119.935 -83.004 -43.23
    Other, Net -0.797 -3.749 1.174 2.019 0.053
    Net Income Before Taxes -95.568 -55.275 -119.337 -81.028 -43.274
    Net Income After Taxes -95.568 -55.275 -119.337 -81.028 -43.274
    Net Income Before Extra. Items -95.568 -55.275 -119.337 -81.028 -43.274
    Net Income -95.568 -55.275 -119.337 -81.028 -43.274
    Income Available to Common Excl. Extra. Items -95.568 -55.275 -119.337 -81.028 -43.274
    Income Available to Common Incl. Extra. Items -95.568 -55.275 -119.337 -81.028 -43.274
    Diluted Net Income -95.568 -55.275 -119.337 -81.028 -43.274
    Diluted Weighted Average Shares 43.7037 43.1818 40.1185 35.1835 28.7724
    Diluted EPS Excluding Extraordinary Items -2.18673 -1.28005 -2.97461 -2.30301 -1.50401
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -2.18673 -2.71607 -2.97461 -2.30301 -1.50401
    Interest Income (Expense), Net Non-Operating 0.04 1.897 -0.576 -0.043 -0.097
    Revenue 65.267 34.897 20.75
    Other Operating Expenses, Total 0.1 0.21 2.203
    Cost of Revenue, Total 7.467 2.304
    Gross Profit 57.8 32.593
    Gain (Loss) on Sale of Assets 0 62.01
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 20.751 20.251 31.447 12.537 10.797
    Revenue 20.751 20.251 31.447 12.537 10.797
    Cost of Revenue, Total 4.649 2.083 2.02 2.475 1.14
    Gross Profit 16.102 18.168 29.427 10.062 9.657
    Total Operating Expense 27.974 27.752 32.6 38.554 50.742
    Selling/General/Admin. Expenses, Total 11.27 11.115 10.793 13.626 23.082
    Research & Development 12.055 10.072 19.787 22.453 26.42
    Operating Income -7.223 -7.501 -1.153 -26.017 -39.945
    Gain (Loss) on Sale of Assets 0 0 0
    Other, Net 1.1 1.111 2.31 -1.509 -1.186
    Net Income Before Taxes -6.123 -6.39 1.157 -27.526 -41.131
    Net Income After Taxes -6.302 -6.39 1.157 -27.526 -41.131
    Net Income Before Extra. Items -6.302 -6.39 1.157 -27.526 -41.131
    Net Income -6.302 -6.39 1.157 -27.526 -41.131
    Income Available to Common Excl. Extra. Items -6.302 -6.39 1.157 -27.526 -41.131
    Income Available to Common Incl. Extra. Items -6.302 -6.39 1.157 -27.526 -41.131
    Diluted Net Income -6.302 -6.39 1.157 -27.526 -41.131
    Diluted Weighted Average Shares 43.6631 43.6716 43.6683 43.7183 43.7188
    Diluted EPS Excluding Extraordinary Items -0.14433 -0.14632 0.0265 -0.62962 -0.94081
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.14433 -0.04369 0.0265 -0.62962 -0.94081
    Other Operating Expenses, Total 0 0 0 0.1
    Unusual Expense (Income) 4.482
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 130.447 202.261 122.363 211.955 151.532
    Cash and Short Term Investments 105.762 181.564 114.634 207.136 147.84
    Cash & Equivalents 105.762 181.564 114.634 207.136 147.84
    Other Current Assets, Total 5.452 7.473 7.729 4.819 3.692
    Total Assets 141.456 212.783 132.047 216.366 151.924
    Property/Plant/Equipment, Total - Net 2.343 5.689 6.394 4.041 0.205
    Other Long Term Assets, Total 5.68 3.17 3.29 0.37 0.187
    Total Current Liabilities 28.284 27.875 19.535 13.586 9.123
    Accounts Payable 14.175 13.552 9.372 8.52 5.872
    Accrued Expenses 14.109 14.323 10.163 5.066 3.251
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 32.235 32.677 26.211 17.463 11.397
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 3.951 4.802 6.676 3.877 2.274
    Total Equity 109.221 180.106 105.836 198.903 140.527
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.004 0.004 0.004 0.004 0.003
    Additional Paid-In Capital 543.929 519.206 391.558 364.712 225.352
    Retained Earnings (Accumulated Deficit) -436.043 -340.475 -285.2 -165.863 -84.835
    Other Equity, Total 1.331 1.371 -0.526 0.05 0.007
    Total Liabilities & Shareholders’ Equity 141.456 212.783 132.047 216.366 151.924
    Total Common Shares Outstanding 43.6701 43.6947 40.6884 39.7284 34.1937
    Total Receivables, Net 12.531 7.712
    Accounts Receivable - Trade, Net 12.531 7.712
    Total Inventory 6.702 5.512
    Intangibles, Net 2.986 1.663
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 124.006 130.447 133.244 153.92 177.739
    Cash and Short Term Investments 92.629 105.762 114.526 133.665 156.724
    Cash & Equivalents 92.629 105.762 114.526 133.665 156.724
    Total Receivables, Net 18.702 12.531 9.251 7.208 9.324
    Accounts Receivable - Trade, Net 18.702 12.531 9.251 7.208 9.324
    Total Inventory 8.945 6.702 6.242 6.794 5.588
    Other Current Assets, Total 3.73 5.452 3.225 6.253 6.103
    Total Assets 137.445 141.456 143.915 165.178 191.047
    Property/Plant/Equipment, Total - Net 1.88 2.343 3.541 3.935 4.852
    Intangibles, Net 2.898 2.986 1.53 1.574 1.618
    Other Long Term Assets, Total 8.661 5.68 5.6 5.749 6.838
    Total Current Liabilities 25.92 28.284 32.015 29.45 29.042
    Accounts Payable 8.843 14.175 13.723 11.291 14.661
    Accrued Expenses 17.077 14.109 18.292 18.159 14.381
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 29.616 32.235 36.017 33.782 33.575
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 3.696 3.951 4.002 4.332 4.533
    Total Equity 107.829 109.221 107.898 131.396 157.472
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.004 0.004 0.004 0.004 0.004
    Additional Paid-In Capital 549.233 543.929 540.392 537.962 524.329
    Retained Earnings (Accumulated Deficit) -442.433 -436.043 -437.2 -409.674 -368.543
    Other Equity, Total 1.025 1.331 4.702 3.104 1.682
    Total Liabilities & Shareholders’ Equity 137.445 141.456 143.915 165.178 191.047
    Total Common Shares Outstanding 43.6778 43.6701 43.6681 43.72 43.7182
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -95.568 -55.275 -119.337 -81.028 -43.274
    Cash From Operating Activities -75.921 -102.556 -91.231 -73.497 -41.229
    Cash From Operating Activities 0.839 0.782 0.396 0.166 0.029
    Non-Cash Items 29.179 -40.779 24.266 4.7 2.063
    Changes in Working Capital -10.371 -7.284 3.444 2.665 -0.047
    Cash From Investing Activities 0 61.043 -2.785 -1.965 -0.234
    Capital Expenditures 0 -0.967 -0.175 -1.965 -0.234
    Cash From Financing Activities 0.084 108.314 2.004 134.704 98.763
    Financing Cash Flow Items -1.002
    Issuance (Retirement) of Stock, Net 0.084 108.314 2.004 134.704 99.765
    Foreign Exchange Effects 0.035 0.129 -0.49 0.023 0.056
    Net Change in Cash -75.802 66.93 -92.502 59.265 57.356
    Other Investing Cash Flow Items, Total 0 62.01 -2.61
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -6.39 -95.568 -96.725 -69.199 -28.068
    Cash From Operating Activities -13.124 -75.921 -67.26 -48.025 -24.925
    Cash From Operating Activities 0.182 0.839 0.609 0.383 0.195
    Non-Cash Items 4.848 29.179 25.763 20.457 5.402
    Changes in Working Capital -11.764 -10.371 3.093 0.334 -2.454
    Cash From Investing Activities 0 0 0 0 0
    Capital Expenditures 0 0 0 0
    Other Investing Cash Flow Items, Total 0 0 0 0 0
    Cash From Financing Activities 0 0.084 0.084 0.032 0.032
    Issuance (Retirement) of Stock, Net 0 0.084 0.084 0.032 0.032
    Foreign Exchange Effects -0.009 0.035 0.138 0.094 0.053
    Net Change in Cash -13.133 -75.802 -67.038 -47.899 -24.84

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Y-mAbs Therapeutics, Inc. Company profile

    About Y-mAbs Therapeutics Inc

    Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Y-mAbs Therapeutics Inc revenues increased 68% to $34.9M. Net loss decreased 54% to $55.3M. Revenues reflect License revenue increase of 59% to $32.9M. Lower net loss reflects Foreign Exchange Gain/LossNon-Business increase from $576K (expense) to $1.9M (income), Licensing royalties decrease of 90% to $210K (expense), Research and development - Balancing val decrease of 2% to $83.5M (expense).

    Industry: Bio Therapeutic Drugs

    230 Park Avenue
    Suite 3350
    NEW YORK
    NEW YORK 10169
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    XRP/USD

    0.52 Price
    +0.300% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    ETH/USD

    1,596.85 Price
    +0.040% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    BTC/USD

    26,632.85 Price
    -0.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading